• 1. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

• Solvents and Organic Chemicals Organic Compounds Lignans, neolignans and related compounds Dibenzylbutane lignans Dibenzylbutane lignans
• Solvents and Organic Chemicals Organic Compounds Lignans, neolignans and related compounds Dibenzylbutane lignans

Comprehensive Overview of Terameprocol (CAS No. 24150-24-1): Mechanism, Applications, and Research Insights

Terameprocol, a synthetic compound with the CAS number 24150-24-1, has garnered significant attention in biomedical research due to its unique mechanism of action and potential therapeutic applications. This small-molecule inhibitor targets transcription factors, particularly Sp1 (specificity protein 1), which plays a pivotal role in cell proliferation and survival pathways. Researchers are increasingly exploring its efficacy in oncology, virology, and inflammatory diseases, aligning with current trends in precision medicine and targeted therapy.

The compound's chemical structure features a tetra-O-methyl nordihydroguaiaretic acid (M4N) backbone, contributing to its stability and bioavailability. Unlike conventional chemotherapeutic agents, Terameprocol selectively disrupts cancer cell metabolism by inhibiting key regulatory proteins, making it a candidate for combination therapy with checkpoint inhibitors or radiation. Recent studies highlight its activity against HPV-associated cancers and glioblastoma multiforme, addressing high-search-volume topics like "novel GBM treatments" and "HPV cancer breakthroughs."

From a pharmacological perspective, Terameprocol exhibits a favorable pharmacokinetic profile, including oral bioavailability and blood-brain barrier penetration—a critical factor for neuro-oncology applications. Its ability to modulate NF-κB and Wnt/β-catenin signaling pathways has sparked interest in inflammatory conditions such as rheumatoid arthritis, tapping into the growing demand for immune-modulating drugs. ClinicalTrials.gov lists ongoing phase II studies evaluating its safety and efficacy, reflecting its transition from bench to bedside.

In drug development circles, CAS 24150-24-1 is frequently discussed alongside transcription factor inhibitors and epigenetic modulators. Analytical methods for its quantification—such as HPLC-MS/MS—are well-documented, supporting quality control in manufacturing. Formulation challenges, including solubility enhancement via lipid-based delivery systems, remain active research areas, coinciding with industry searches for "improved drug delivery technologies."

Beyond oncology, Terameprocol shows promise in antiviral research, particularly against DNA viruses like herpes simplex and cytomegalovirus. This aligns with post-pandemic interest in "broad-spectrum antivirals." Its dual antioxidant and anti-angiogenic properties further expand potential applications to age-related macular degeneration (AMD) and diabetic retinopathy—conditions with rising global prevalence.

Regulatory status varies by region, with orphan drug designations for specific indications accelerating development. Patent landscapes reveal strategic protections for crystal polymorphs and combination formulations, reflecting commercial interest. As synthetic biology advances, Terameprocol derivatives engineered for improved target selectivity may emerge, addressing the pharmaceutical industry's focus on next-generation therapeutics.

For researchers investigating Sp1-dependent pathologies or clinicians tracking experimental cancer therapies, Terameprocol represents a compelling case study in translational medicine. Its multifaceted activity underscores the importance of polypharmacology in modern drug discovery—a concept gaining traction in response to complex diseases. With over 200 peer-reviewed publications referencing CAS 24150-24-1, the compound continues to generate robust academic and industrial engagement worldwide.

• 5701-82-6(Terameprocol)
• 108996-61-8(1,2-dimethoxy-4-(3-methylbutyl)benzene)
• 688318-61-8(Benzene, 1,2-dimethoxy-4-(4-methylpentyl)-)
• 655228-96-9(Phenol,4-[(2R,3S)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-2-methoxy-)
• 121209-88-9((±)-Dihydroguaiaretic Acid)
• 688318-82-3(Benzene, 1,2-dimethoxy-4-(3-methylpentyl)-)
• 66322-34-7(Dihydroguaiaretic acid)
• 36469-60-0(Phenol,4,4'-(2,3-dimethyl-1,4-butanediyl)bis[2-methoxy-)
• 54473-24-4(1,2-Benzenediol,4-[4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbutyl]-)
• 688318-53-8(Benzene, 1,2-dimethoxy-4-(2-methylbutyl)-)